Evidence map›Paper›PMID 28203069›Full record

ArticleInternational journal of chronic obstructive pulmonary disease2017

The pharmacological cost of COPD during Greek economic crisis.

Eirini Stafyla, Theodora Kerenidi, Irini Gerogianni, Mary Geitona, Zoe Daniil, Konstantinos I Gourgoulianis

Open access · goldAbstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of chronic obstructive pulmonary disease, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Impact of the financial crisis on COPD burden: Greece as a case study.European respiratory review : an official journal of the European Respiratory Society · 2018
    Review
  5. The annual direct costs of stable COPD in Greece.International journal of chronic obstructive pulmonary disease · 2018
    Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Eirini StafylaRespiratory Medicine Department, University of Thessaly School of Medicine, University Hospital of Larissa, Larissa.
Theodora KerenidiRespiratory Medicine Department, University of Thessaly School of Medicine, University Hospital of Larissa, Larissa.
Irini GerogianniRespiratory Medicine Department, University of Thessaly School of Medicine, University Hospital of Larissa, Larissa.
Mary GeitonaDepartment of Social Policy, University of Peloponnese, Korithos, Greece.
Zoe DaniilRespiratory Medicine Department, University of Thessaly School of Medicine, University Hospital of Larissa, Larissa.
Konstantinos I GourgoulianisRespiratory Medicine Department, University of Thessaly School of Medicine, University Hospital of Larissa, Larissa.
University of Thessaly · GRUniversity of Peloponnese · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThe economic crisis in Greece has substantially affected patients with COPD. The reduction of disposable income has its consequences on patients' ability to afford their medication. The aim of the study is to evaluate the cost of treatment for patients with COPD and the influence of the financial crisis to the patients.

methodsData were collected from 189 patients (male: 178, mean age: 70.1±8.4) who visited the outpatient department of University Hospital of Larissa in 2014 and 2015. The pharmacological cost of treatment was calculated based on national pharmaceutical formulary prices.

resultsCOPD patients were classified into four stages according to Global Initiative for Chronic Obstructive Lung Disease (GOLD): 7.4% were in stage I, 43.4% in stage II, 34.4% in stage III, and 14.8% in stage IV. Patients were graded as per GOLD as follows: 18% as grade A, 14.3% as B, 23.3% as C, and 44.4% as D. The annual cost of COPD maintenance treatment per patient was €952.92 (±398.01), of which €239.91 were patients' expenses. The annual treatment cost for stable disease ranged from €615.44 to €1302.03 depending on disease stages (GOLD stages I-IV) and from €715.01 to €1101.05 depending on GOLD grades (grades A-D). The cost of maintenance medication was statistically and significantly higher for patients with advanced disease (GOLD stages III-IV) and for patients at high risk (GOLD grades C-D [

conclusionThe pharmacological cost of treatment for COPD patients seems to be considerably high, in all disease stages. As the average income is decreased, patients face difficulties to afford inhaled medication.

Indexed as

Drug CostsEconomic RecessionFinancing, PersonalAdministration, InhalationAgedBronchodilator AgentsFemaleForced Expiratory VolumeGreeceHealth ExpendituresHospitals, UniversityHumansIncomeLungMaleMiddle AgedBronchodilator AgentsCOPDeconomic crisismaintenance treatmentpharmacological cost

Identifiers

PMID28203069
PMCPMC5293366
OpenAlexW2585932201

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.